The impact of ERBB2 alterations in muscle-invasive bladder cancer after neoadjuvant chemotherapy
British Journal of Urology International (BJUI)
Earle F. Burgess, Hilary Elom, Landon C. Brown, Michael McCormack, Ericson Stoen, Metamia Ciampricotti, Edward Williams, James T. Symanowski
Excerpt
Cisplatin-based neoadjuvant chemotherapy (NAC) has been a standard treatment for muscle-invasive bladder cancer (MIBC), although peri-operative management is evolving to include immune checkpoint inhibitor (ICI) and enfortumab vedotin (EV)-based regimens. Despite these advances, access to EV and ICIs remains limited in much of the world, and cisplatin-based NAC continues to represent a standard option for a large proportion of patients globally. Identification of biomarkers associated with response to NAC therefore remains clinically important.
Both pathogenic ERBB2 mutations and gene amplification are well-recognized genomic alterations in MIBC.3 Prior studies have reported conflicting findings regarding the association of ERBB2 mutations and amplification with response to NAC in MIBC,4-6 which may be due to heterogeneity in chemotherapy regimens, genomic sequencing methodologies and definitions of treatment response across these studies. These discordant results highlight the need for additional study to clarify the prognostic value of ERBB2 alterations in MIBC.
Related publications